clinical trial · NCT00834535
Cefdinir Capsules 300 mg, Non-fasting
Teva Pharmaceuticals USA·phase1·completed·n = 32
HealthyCefdinir Capsules 300 mgOMNICEF® Capsule 300 mg
brief summary
This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting conditions.
started
Jul 1, 2005
primary completion
Aug 1, 2005
completion
Aug 1, 2005
last updated
Aug 20, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Non-fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol